| Literature DB >> 35062776 |
Roger Książek1, Radosław Kapłan1, Katarzyna Gdowska1, Piotr Łebkowski1.
Abstract
The paper is devoted to optimal vaccination scheduling during a pandemic to minimize the probability of infection. The recent COVID-19 pandemic showed that the international community is not properly prepared to manage a crisis of this scale. Just after the vaccines had been approved by medical agencies, the policymakers needed to decide on the distribution strategy. To successfully fight the pandemic, the key is to find the equilibrium between the vaccine distribution schedule and the available supplies caused by limited production capacity. This is why society needs to be divided into stratified groups whose access to vaccines is prioritized. Herein, we present the problem of distributing protective actions (i.e., vaccines) and formulate two mixed-integer programs to solve it. The problem of distributing protective actions (PDPA) aims at finding an optimal schedule for a given set of social groups with a constant probability of infection. The problem of distributing protective actions with a herd immunity threshold (PDPAHIT) also includes a variable probability of infection, i.e., the situation when herd immunity is obtained. The results of computational experiments are reported and the potential of the models is illustrated with examples.Entities:
Keywords: COVID-19 vaccination; decision-making; herd immune; mathematical model; optimization; scheduling; vaccination schedule
Year: 2022 PMID: 35062776 PMCID: PMC8781133 DOI: 10.3390/vaccines10010116
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
The main factors underlying severe COVID-19 infection [10].
| Age Range [Years] | Cases | Hospitalization | Death |
|---|---|---|---|
| 0–4 | <1x | 2x | 2x |
| 5–17 | Reference group | Reference group | Reference group |
| 18–29 | 2x | 6x | 10x |
| 30–39 | 2x | 10x | 45x |
| 40–49 | 2x | 15x | 130x |
| 50–64 | 2x | 25x | 440x |
| 65–74 | 1x | 40x | 1300x |
| 75–84 | 1x | 65x | 3200x |
| 85+ | 2x | 95x | 8700x |
Characteristics of vaccines [11,12,13,14].
| Characteristics | Vaccines | |||
|---|---|---|---|---|
| Pfizer | Moderna | AstraZeneca | JohnsonAndJohnson | |
| Number of doses | 2 | 2 | 2 | 1 |
| Vaccine efficacy against COVID-19 | 0.950 | 0.941 | 0.595 | 0.669 |
| Vaccine efficacy against severe COVID-19 | no data | 1 | 1 | 0.854 |
Notation.
|
| ||
|
| = | the set of identical consecutive planning periods; |
|
| = | the set of available protective measures (e.g., different preparations) to prevent an adverse phenomenon (e.g., death, disease); |
|
| = | the set of homogeneous social groups defined based on a selected criterion (e.g., age, occupation, place of residence); |
|
| ||
|
| – | a sufficiently large constant; |
|
| – | the size of the group |
|
| – | the probability of occurrence of an adverse phenomenon in a person in a given group |
|
| – | the probability of occurrence of an adverse phenomenon in an individual covered by protective action |
|
| – | maximum available number of units of protective action |
|
| – | maximum available number of units of all protective actions in period |
|
| – | the percentage of applied protective actions ensuring collective immunity of the community to the adverse phenomenon; |
|
| ||
|
| – | the number of individuals subjected to the protective action |
|
| – | the expected value of the number of individuals in group |
|
| = | 1 if group |
Assumed territorial division.
| Name | Population Size | pR |
|---|---|---|
| District 1 | 2,901,225 | 0.01 |
| District 2 | 2,077,775 | 0.06 |
| District 3 | 2,117,619 | 0.05 |
| District 4 | 1,014,548 | 0.08 |
| District 5 | 2,466,322 | 0.03 |
| District 6 | 3,400,577 | 0.03 |
| District 7 | 5,403,412 | 0.07 |
| District 8 | 986,506 | 0.04 |
| District 9 | 2,129,015 | 0.09 |
| District 10 | 1,181,533 | 0.09 |
| District 11 | 2,333,523 | 0.07 |
| District 12 | 4,533,565 | 0.04 |
| District 13 | 1,241,546 | 0.06 |
| District 14 | 1,428,983 | 0.09 |
| District 15 | 3,493,969 | 0.06 |
| District 16 | 1,701,030 | 0.09 |
Assumed vaccine parameters.
| Name | pR |
|---|---|
| Vaccine 1 | 0.950 |
| Vaccine 2 | 0.941 |
| Vaccine 3 | 0.595 |
| Vaccine 4 | 0.669 |
Assumed schedule of vaccine delivery [the number of people who can be vaccinated].
| Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
|---|---|---|---|---|
| 0 | 873,000 | 0 | 172,000 | 0 |
| 1 | 873,000 | 204,000 | 161,000 | 0 |
| 2 | 873,000 | 0 | 268,000 | 300,000 |
| 3 | 873,000 | 287,000 | 765,000 | 0 |
| 4 | 873,000 | 0 | 172,000 | 0 |
| 5 | 873,000 | 204,000 | 161,000 | 0 |
| 6 | 873,000 | 0 | 268,000 | 300,000 |
| 7 | 873,000 | 287,000 | 765,000 | 0 |
| 8 | 873,000 | 0 | 172,000 | 0 |
| 9 | 873,000 | 204,000 | 161,000 | 0 |
| 10 | 873,000 | 0 | 268,000 | 300,000 |
| 11 | 873,000 | 287,000 | 765,000 | 0 |
Model PDPA—District 10.
| Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
|---|---|---|---|---|
| 0 | 172,000 | 0 | 0 | 0 |
| 1 | 0 | 0 | 204,000 | 0 |
| 2 | 0 | 0 | 0 | 0 |
| 3 | 92,911 | 0 | 0 | 630,527 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
| 6 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 | 0 |
| 9 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 |
| 11 | 0 | 0 | 0 | 0 |
Model PDPAHIT—District 10.
| Period | Vaccine 1 | Vaccine 2 | Vaccine 3 | Vaccine 4 |
|---|---|---|---|---|
| 0 | 172,000 | 0 | 0 | 714,150 |
| 1 | 0 | 0 | 0 | 0 |
| 2 | 0 | 0 | 0 | 0 |
| 3 | 0 | 0 | 0 | 0 |
| 4 | 0 | 0 | 0 | 0 |
| 5 | 0 | 0 | 0 | 0 |
| 6 | 0 | 0 | 0 | 0 |
| 7 | 0 | 0 | 0 | 0 |
| 8 | 0 | 0 | 0 | 0 |
| 9 | 0 | 0 | 0 | 0 |
| 10 | 0 | 0 | 0 | 0 |
| 11 | 0 | 0 | 0 | 0 |
Figure 1The results obtained using the PDPA model for the entire population.
Figure 2The results obtained using the PDPAHIT model for the entire population.